Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: juvenile idiopathic arthritis

How to Effectively Diagnose & Treat Macrophage Activation Syndrome

Vanessa Caceres  |  May 30, 2024

“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).

Filed under:ConditionsPediatric ConditionsVasculitis Tagged with:hemophagocytic lymphohistiocytosis (HLH)macrophage activation syndromeMASpatient care

Case Report: Complicated Presentation Eventually Explained by Rare Syndrome

Geoffrey E. Thiele, MD, & Iris Reyhan, MD  |  April 10, 2024

Pachydermoperiostosis (PDP), also known as Touraine-Solente-Golé syndrome or primary hypertrophic osteoarthropathy, is a rare syndrome that can be inherited as autosomal dominant, autosomal recessive, or sporadically. This progressive disease primarily affects males, who tend to have more severe features than females. PDP usually occurs during adolescence, often starting around puberty.1 The main clinical features are…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportCrohn's diseasePachydermoperiostosisprimary hypertrophic osteoarthropathyTouraine-Solente- Golé syndrome

Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals

Thomas R. Collins  |  January 4, 2024

An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.

Filed under:ACR ConvergenceAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2023ApprovalsBiosimilarsU.S. Food and Drug Administration (FDA)

Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology

Glen Rodman  |  December 6, 2023

SAN DIEGO—At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.

Filed under:ACR ConvergenceConditionsGuidanceLegislation & AdvocacyLegislation & AdvocacyMeeting ReportsMeeting ReportsPediatric ConditionsProfessional Topics Tagged with:ACR Convergence 2023Juvenile Arthritis (JIA)reproductive rights

Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology

Glen Rodman  |  December 5, 2023

At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.

Filed under:ACR ConvergenceConditionsGuidanceLegislation & AdvocacyLegislation & AdvocacyMeeting ReportsMeeting ReportsPediatric ConditionsProfessional Topics Tagged with:abortionACR Convergence 2023Juvenile Arthritis (JIA)reproductive rights

The Eyes Have It

Jason Liebowitz, MD, FACR  |  November 14, 2023

SAN DIEGO—Many rheumatologists see patients referred for uveitis, and Laura Kopplin, MD, PhD, assistant professor of ophthalmology and visual sciences, University of Wisconsin, Madison, discussed inflammatory disease of the eye at ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2023panuveitisUveitis

FDA Approves Canakinumab to Treat Gout Flares

Michele B. Kaufman, PharmD, BCGP  |  November 3, 2023

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

Filed under:Biologics/DMARDsDrug UpdatesGout and Crystalline Arthritis Tagged with:canakinumabFDA approvalGout Resource CenterU.S. Food and Drug Administration (FDA)

Get Your Patients Moving: Physical Activity Is Key for Pain Management & Overall Health

Vanessa Caceres  |  October 13, 2023

Regular movement is crucial for everyone, but patients with rheumatic disease may feel overwhelmed about starting and maintaining a routine. Here’s how physical and occupational therapists can help patients establish and reach movement goals, while improving their pain management and overall health.

Filed under:ConditionsPain Syndromes Tagged with:ACR on AirACR on Air podcastExercisePain Syndrome FocusRheumPhysical Therapy

FDA Grants Interchangeable Designation to Pfizer’s Abrilada, Biosimilar to AbbVie’s Humira

Keri Losavio  |  October 5, 2023

On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesPsoriatic ArthritisRheumatoid Arthritis Tagged with:Humirainterchangeability

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  September 11, 2023

RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

Filed under:Career DevelopmentConditionsEducation & TrainingProfessional TopicsResearch ReviewsResearch RheumRheumatoid ArthritisVasculitis Tagged with:AAV FocusRheumANCA-Associated VasculitisAntibodiescyclophosphamideetanerceptFellowsFellows-in-TrainingGlucocorticoidsonline educationpreclinicalprednisoneRheumatology Research FoundationRheumMadnessrituximabTNF-Alpha inhibitor

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 37
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences